Houston, TX, (August 9, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announces that it has entered into a collaborative research agreement with Imperial College London for research studies using the company's proprietary antimicrobial nucleic acid compound.
Professor Martin Buck of the Division of Biology at Imperial is the Principal Investigator for this research program to further elucidate the antimicrobial activity of CytoGenix RBL-1 compound. Dr. Buck's scientific interests include the understanding of the molecular biology of bacteria particularly the specific function of bacterial RNA.
Dr. Yin Chen, CytoGenix Vice President of Research and Chief Scientific Officer commented, "We are very pleased to collaborate with scientists of the caliber of Dr. Buck. The results of his work will further our understanding of this promising therapeutic compound."
About Imperial College London
Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality.
Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment - underpinned by a dynamic enterprise culture. Website: www.imperial.ac.uk.
About CytoGenix
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (800) 677-5707
